文献速递胸部PETCT

EGFR突变转移性肺腺癌的预后因素

Prognostic factors of EGFR-mutated metastatic adenocarcinoma of lung.
PubMed 文献 · Eur J Radiol · 2019-12-10

回顾性分析41例接受一线TKI治疗的EGFR突变转移性肺腺癌患者,评估10项潜在影响无进展生存的因素。Mantel-Cox检验显示原发灶SUVmax、血清CEA水平、性别和吸烟史为重要预后因素,P值分别为0.001、0.023、0.034和0.041。低原发SUVmax、低血清CEA、女性和从不吸烟提示对TKI反应良好。

要点

  • 原发灶SUVmax是四项预后因素中可能最重要的一项(P=0.001)。
  • 低原发SUVmax和低血清CEA提示TKI治疗反应良好。
  • 女性及从不吸烟者预后较好(P分别为0.034和0.041)。

诊断标准与关键数值

  • 原发灶SUVmax的Mantel-Cox检验P=0.001。
  • 血清CEA水平的Mantel-Cox检验P=0.023。
  • 性别的Mantel-Cox检验P=0.034。
  • 吸烟史的Mantel-Cox检验P=0.041。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

PURPOSE: The first-line treatment of metastatic lung adenocarcinoma with epidermal growth factor receptor (EGFR) mutation is tyrosine kinase inhibitor (TKI). This study aimed to evaluate potential factors affecting the progression-free survival under TKI treatment.

METHODS: Forty one patients with EGFR-mutated metastatic lung adenocarcinoma under first-line TKI treatment were retrospectively evaluated. Ten factors potentially influencing the progression-free survival were studied: patients' age, gender, smoking history, number of comorbidities, performance status, tumor mutation site, maximum of standardized uptake value (SUVmax) of primary tumor in FDG PET/CT, serum CEA level, number of metastatic organs and presence of pleural/pericardial effusion. Mantel-Cox tests and waterfall plots were performed for statistical analyses.

RESULTS: Statistical evaluation demonstrated that primary SUVmax, serum CEA level, gender and smoking history were important prognostic factors, with corresponding p values of 0.001, 0.023, 0.034 and 0.041 respectively in Mantel-Cox analyses.

CONCLUSION: Low primary SUVmax, low serum CEA level, female and never smoker were four prognostic factors suggestive of good response to TKI in mutated EGFR metastatic lung adenocarcinoma. SUVmax is probably the most important among the four factors.

来源:Eur J Radiol,查看原文。版权归原作者所有。

引用

  1. Ng KS, King Sun C, Boom Ting K, et al. Prognostic factors of EGFR-mutated metastatic adenocarcinoma of lung. Eur J Radiol. 2019. PMID: 31846863. doi:10.1016/j.ejrad.2019.108780

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。